Open menu

Nanotechnology General News

The latest news from academia, regulators
research labs and other things of interest

Posted: March 5, 2008

Arrowhead CEO to Present Objectives for 2008 via Webcast Following Annual Meeting of Shareholders

(Nanowerk News) Arrowhead Research Corporation announced today that Dr. Christopher Anzalone, Arrowhead’s Chief Executive Officer and President, will present the Company’s strategic plan and objectives for 2008 at 10:30 am PT on March 13, 2008, following the scheduled Annual Meeting of Shareholders.
The presentation, followed by a question and answer period, will be broadcast live via the Internet and by teleconference beginning at 10:30 am, and a replay will be available for those who are unable to attend the live broadcast. Information on how to access the webcast will be posted on Arrowhead’s website by Monday, March 10 at
About Arrowhead Research Corporation
Arrowhead Research Corporation ( (NASDAQ:ARWR) is a leading nanotechnology company commercializing new technologies in the areas of life sciences, electronics and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has five subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, fullerene anti-oxidants, carbon-based electronics and compound semiconductor materials.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our clinical studies, our ability to successfully develop and manufacture products, rapid technological change in our industry, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
Source: Arrowhead Research Corporation
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
If you liked this article, please give it a quick review on reddit or StumbleUpon. Thanks!
These articles might interest you as well: